Q-omics provides the consensus-scored UNC13D profile across patient tissues and cancer cell-line models. UNC13D expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UNC13D is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, UNC13D protein abundance shows 33,038 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where UNC13D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UNC13D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UNC13D survival associations across molecular data types. UNC13D RNA expression shows survival associations in the most cancer types (29), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UNC13D RNA expression–survival associations across cancer types. High UNC13D expression shows unfavorable associations in KIRC, KIRP, OV, PAAD, LAML and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UNC13D RNA expression.
This table summarizes UNC13D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UNC13D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UNC13D shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, KIRP, BLCA and STAD. The KIRC box plot shows higher UNC13D RNA expression in tumor versus normal tissue (log2 FC = +1.438, t-test p < 0.001).
This table shows molecular features associated with UNC13D in patient tissues and cancer cell lines. In patient samples, UNC13D shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, UNC13D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
